depression
Conditions
Interventions
Experimental group:Modified Xiaoyao Powder
Control group:Modified Xiaoyao Powder placebo
Sponsors
Hospital of Chengdu University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 65 years men and women; 2. Patients who had received a diagnosis of COPD combined mild to moderate depression (HAMD-17 score 7 to 24) and meet the syndrome of stagnation of liver qi of depression; 3. The course of depression does not exceed 3 months; 4. The patients has not taken antidepressants in the past 1 month; 5. Agree to participate and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. A history of a suicide attempt treament-resistant depression, and familial mental illness; 2. Had a recent history of other acute or chronic significant clinical manifestations medical conditions; 3. A history of bipolar disorder, schizophrenia, or schizo affective disorder; 4. Patients who cannot actively cooperate with the treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the change in the HAMD-17 score from baseline; | — |
Secondary
| Measure | Time frame |
|---|---|
| a reduction of more than 50% from baseline in the HAMD-17 score;the change from baseline in CAT score;the change from baseline in mMRC score;the frequency of hospitalizations;the number of exacerbations; | — |
Countries
China
Contacts
Public ContactKeling Chen
Chengdu University of Traditional Chinese Medicine
Outcome results
None listed